These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 14671165)

  • 21. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P; Clemmesen B; Christiansen C
    Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
    Bone HG; Downs RW; Tucci JR; Harris ST; Weinstein RS; Licata AA; McClung MR; Kimmel DB; Gertz BJ; Hale E; Polvino WJ
    J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoporosis in men: a potential role for the sex hormone binding globulin.
    Legrand E; Hedde C; Gallois Y; Degasne I; Boux de Casson F; Mathieu E; Baslé MF; Chappard D; Audran M
    Bone; 2001 Jul; 29(1):90-5. PubMed ID: 11472897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low body size and elevated sex-hormone binding globulin distinguish men with idiopathic vertebral fracture.
    Evans SF; Davie MW
    Calcif Tissue Int; 2002 Jan; 70(1):9-15. PubMed ID: 11907702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
    Amin S; Riggs BL; Melton LJ; Achenbach SJ; Atkinson EJ; Khosla S
    J Bone Miner Res; 2007 Jun; 22(6):799-807. PubMed ID: 17352648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
    Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
    Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of alendronate on bone density in men with primary and secondary osteoporosis.
    Ho YV; Frauman AG; Thomson W; Seeman E
    Osteoporos Int; 2000; 11(2):98-101. PubMed ID: 10793867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
    Boonen S; Rosen C; Bouillon R; Sommer A; McKay M; Rosen D; Adams S; Broos P; Lenaerts J; Raus J; Vanderschueren D; Geusens P
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1593-9. PubMed ID: 11932288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.
    Donaldson MG; Palermo L; Ensrud KE; Hochberg MC; Schousboe JT; Cummings SR
    J Bone Miner Res; 2012 Aug; 27(8):1804-10. PubMed ID: 22492479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of male osteoporosis: recent advances with alendronate.
    Ringe JD; Orwoll E; Daifotis A; Lombardi A
    Osteoporos Int; 2002 Mar; 13(3):195-9. PubMed ID: 11991437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
    Greenspan SL; Resnick NM; Parker RA
    J Clin Endocrinol Metab; 2005 May; 90(5):2762-7. PubMed ID: 15713726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
    Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
    Yonsei Med J; 2009 Aug; 50(4):474-81. PubMed ID: 19718394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.